Overview

Study of KN026 Monotherapy or Combination Therapy in Patients With Metastatic Breast Cancer

Status:
Recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
This is an open-label, three-cohort phase 2 study of KN026 in subjects with advanced breast Cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Treatments:
Docetaxel